POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION.

Annals of the Rheumatic Diseases

X. Baraliakos, A. Deodhar, D. van der Heijde, F. van den Bosch, M. Magrey, W.P. Maksymowych, T. Tomita, H. Xu, D. Voiniciuc, C. Prajapati, M. Manente, A. Marten, L.S. Gensler. POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION. Annals of the Rheumatic Diseases. 2025 Jun 1; 84:947-948.

2025

https://researcherprofiles.org/profile/636099773

X. Baraliakos, A. Deodhar, D. van der Heijde, F. van den Bosch, M. Magrey, W.P. Maksymowych, T. Tomita, H. Xu, D. Voiniciuc, C. Prajapati, M. Manente, A. Marten, L.S. Gensler

Search form

You are here

POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION.